Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to “Market Perform” at Leerink Partners

Leerink Partners lowered shares of Compass Therapeutics (NASDAQ:CMPX) from an outperform rating to a market perform rating in a report published on Friday, Marketbeat reports. The firm currently has $4.00 price target on the stock, down from their previous price target of $5.00.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. Finally, Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Stock Down 2.2 %

Compass Therapeutics stock opened at $1.35 on Friday. The firm has a 50 day moving average price of $1.75 and a 200-day moving average price of $1.41. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The company has a market capitalization of $185.75 million, a P/E ratio of -3.65 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Equities analysts expect that Compass Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the period. Barclays PLC raised its position in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares in the last quarter. XTX Topco Ltd bought a new stake in Compass Therapeutics during the third quarter valued at $37,000. The Manufacturers Life Insurance Company purchased a new position in Compass Therapeutics during the third quarter worth about $79,000. Finally, Intech Investment Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth about $30,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.